| Cellectricon–Censo Biotechnologies: drug discovery services, 201701– collab offer joint tech access program for human iPSC-based discovery services |
2017-01-26 |
| Oxford BioTherapeutics–Wafra: credit, 201701– senior secured term loan $10m from Oxford Finance LLC |
2017-01-26 |
| Bactevo–United Kingdom (govt): grant, 201701 Biomedical Catalyst grant £1.5m from Innovate UK |
2017-01-25 |
| Atlas Genetics–SEVERAL: investment, 201701 financing round Series D £26.25m |
2017-01-23 |
| Luxendo–Huntsworth: public relations, 201701 service existent by Citigate Dewe Rogerson |
2017-01-12 |
| United Kingdom (govt)–Intellia Therapeutics: genomics, 201701– collab Intellia joins Genomics England GENE Consortium for 100,000 Genomes Project |
2017-01-11 |
| Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs |
2017-01-10 |
| Crescendo Biologics–Sofinnova: investment, 201701 existing investor Sofinnova Partners |
2017-01-10 |
| Crescendo Biologics–Touchstone Innovations: investment, 201701 existing investor Touchstone Innovations |
2017-01-10 |
| Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m |
2017-01-09 |
| Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital |
2017-01-09 |
| Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al |
2017-01-09 |
| Kymab–Gates Foundation: grant, 201701– grant $9m over 3 years for infectious disease RnD |
2017-01-09 |
| Macrophage Pharma–Aglaia: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–Chroma Therapeutics: cancer immunotherapy, 201701 acquisition of ESM technology w discovery stage theapeutic assets by Macrophage |
2017-01-09 |
| Macrophage Pharma–Novo Group: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–SEVERAL: investment, 201701 financing round Series A £9m led by CRT Pioneer Fund + incl Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–Sixth Element Capital: investment, 201701 financing round Series A totalling £9m incl lead investor CRT Pioneer Fund |
2017-01-09 |
| Sixth Element Capital–Hume Brophy: public relations, 201701 service existent by Hume Brophy London |
2017-01-09 |
| Nerre Therapeutics–Huntsworth: public relations, 201701 service existent by Citigate Dewe Rogerson |
2017-01-05 |
| Nerre Therapeutics–SEVERAL: investment, 201701 financing round Series B £23m from Fountain Healthcare + Forbion + Orbimed + Novo + Advent |
2017-01-05 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| Innate Pharma–Consilium: public relations, 201701 service existent by Consilium Strategic Communications |
2017-01-04 |
| Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 |
2017-01-04 |
| Amplyx Pharmaceuticals–Arix Bioscience: investment, 2017 investment £2.9m during 2017 from new investor Arix results in shareholding of 2.8% |
2017-01-01 |
| Amplyx Pharmaceuticals–SEVERAL: investment, 2017 financing round Series C $67m incl new + co-investor Arix Bioscience |
2017-01-01 |
| Artios Pharma–Arix Bioscience: investment, 2017 investment £1.8m during 2017 from existing investor Arix bringing total shareholding to 14.7% |
2017-01-01 |
| AstraZeneca–N-Side: supply chain services, 2017– supply consulting for clinical trial supply chain management |
2017-01-01 |
| Atox Bio–Arix Bioscience: investment, 2017 investment £3m during 2017 from new investor Arix results in shareholding of 3.7% |
2017-01-01 |
| Atox Bio–SEVERAL: investment, 2017 financing round Series F $30m incl new + lead investor Arix Bioscience |
2017-01-01 |
| Aura Biosciences–Arix Bioscience: investment, 2017 investment £2.5m during 2017 from new investor Arix results in shareholding of 4.9% |
2017-01-01 |
| Aura Biosciences–SEVERAL: investment, 2017 financing round Series C $30m incl new + co-lead investor Arix Bioscience |
2017-01-01 |
| Depixus–Arix Bioscience: investment, 2017 investment £0.3m during 2017 from existing investor Arix results in shareholding of 17.6% |
2017-01-01 |
| Horizon Discovery–ERS Genomics: CRISPR technology, 201701– license ww non-excl expansion |
2017-01-01 |
| Neuro-Bio–SEVERAL: investment, 2017 financing round Series A incl investor Kairos Ventures |
2017-01-01 |
| OptiKira–Arix Bioscience: investment, 2017 investment £0.4m during 2017 from existing investor Arix results in shareholding of 26% |
2017-01-01 |
| Oxford Genetics–ERS Genomics: CRISPR technology, 2017– license non-excl for CRISPR modified cell lines for US + Europe |
2017-01-01 |
| Oxford VR–SEVERAL: investment, 201701 seed financing round led by Oxford Sciences Innovation |
2017-01-01 |
| PreciThera–Arix Bioscience: investment, 2017 investment £0.5m during 2017 from new investor Arix results in shareholding of 17.8% |
2017-01-01 |
| PreciThera–SEVERAL: investment, 2017 financing round Series A $29m incl new + co-lead investor Arix Bioscience |
2017-01-01 |
| Ridgeway Biologicals–Klocke: investment, 201701 acquisition of Ridgeway Biologicals by IDT Biologika |
2017-01-01 |
| Verona Pharma–Arix Bioscience: investment, 2017 investment £1.8m during 2017 from existing investor Arix results in shareholding of 2.5% |
2017-01-01 |
| PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) |
2016-12-22 |
| Yourgene Bioscience–Premaitha: investment, 201612–201702 acquisition of Yourgene Bioscience Co Ltd by Premaitha Health plc |
2016-12-21 |
| Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma |
2016-12-20 |
| Microbiotica–Cambridge Innovation Capital: investment, 201612 seed funding round totalling £8m with £4m from CIC + IP Group each |
2016-12-19 |
| Microbiotica–IP Group: investment, 201612 seed funding round totalling £8m with £4m from CIC + IP Group each |
2016-12-19 |
| Microbiotica–SEVERAL: investment, 201612 seed funding round £8m co-led by Cambridge Innovation Capital + IP Group |
2016-12-19 |
| Parkwalk Advisors–IP Group: investment, 201612–201702 acquisition £5m upfront cash + £2.5m upfront shares + £5m cash + £5m shares milestones |
2016-12-16 |
| Novacyt–SEVERAL: investment, 201612 private placement €2.725m with 2.725m new shares = dilution of 15.8% |
2016-12-15 |
| PDC*line Pharma–Andrew Lloyd Associates: public relations, 201612 service existent by ALA |
2016-12-06 |
| Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene |
2016-12-01 |
| Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II |
2016-12-01 |
| Autolus–United Kingdom (govt): cell therapy manfucturing, 201611– Autolus to use CGT Catapult manufacturing centre in Stevenage |
2016-11-22 |
| Atopix Therapeutics–Chiesi: investment, 201611 acquisition by Chiesi |
2016-11-21 |
| Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI |
2016-11-10 |
| Ervaxx–OTHER: investment, 201611–201911 financing round seed/Series A totalling $17.5m incl undisclosed global pharma company |
2016-11-08 |
| Ervaxx–SEVERAL: investment, 201611–201911 financing round seed/Series A $17.5m from SV Health Investors + global pharma company |
2016-11-08 |
| Ervaxx–SV Health investors: investment, 201611–201911 financing round seed/Series A totalling $17.5m incl seed investor SV Health Investors |
2016-11-08 |
| Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution |
2016-11-07 |
| International Laboratory Services (GB)–Eurofins: investment, 201610 acquisition of ILS Ltd by Eurofins Food and Water Testing UK + IE |
2016-10-24 |
| Vitae–Allergan: investment, 201609 acquisition $640m of Vitae Pharmaceuticals Inc by Allergan plc |
2016-09-14 |
| Inflazome–Fountain Healthcare Partners: investment, 201609 financing round Series A totalling $17m incl founding investor FHP |
2016-09-12 |
| Inflazome–Novartis: investment, 201609 financing round Series A totalling $17m incl founding investor Novartis Venture Fund |
2016-09-12 |
| Inflazome–SEVERAL: investment, 201609 financing round Series A $17m from Novartis Venture Fund + Fountain Healthcare Partners |
2016-09-12 |
| Fluidic Analytics–SEVERAL: investment, 201609 financing round Series B £5.3m ($6.9m) led by IQ Capital Partners |
2016-09-06 |
| Xconomy–Informa: investment, 201608 acquisition 100% £1m upfront + £1.5m milestones+deferred of Xconomy Inc by Informa |
2016-08-31 |
| Evonetix–Cambridge Consultants: investment, 201607 spin-off of Evonetix Ltd as joint venture of Cambridge Consultants + Hermann Hauser |
2016-07-19 |
| Evonetix–PERSON: investment, 201607 spin-off of Evonetix Ltd as joint venture of Cambridge Consultants + Hermann Hauser |
2016-07-19 |
| Evonetix–SEVERAL: investment, 201607 spin-off of Evonetix Ltd as joint venture of Cambridge Consultants + Hermann Hauser |
2016-07-19 |
| NodThera–Epidarex Capital: investment, 201607 seed funding from Epidarex Capital |
2016-07-15 |
| Delenex–Cell Medica: investment, 201607 acquisition €na of Delenex Pharmaceuticals AG by Cell Medica |
2016-07-12 |
| Leo Pharma–AstraZeneca: therap antibodies, 201607– excl rights to develop + commercialise tralokinumab + brodalumab in Europe |
2016-07-01 |
| Verona Pharma–LCF Rothschild: investment, 201607 investment by EdRIP |
2016-07-01 |
| Storm Therapeutics–Cambridge Innovation Capital: investment, 201606 financing round Series A totalling £12m incl investor CIC |
2016-06-28 |
| Storm Therapeutics–Merck (DE): investment, 201606 financing round Series A totalling £12m incl investor Merck Ventures |
2016-06-28 |
| Storm Therapeutics–Pfizer: investment, 201606 financing round Series A totalling £12m incl investor Pfizer Venture Investments |
2016-06-28 |
| Storm Therapeutics–SEVERAL: investment, 201606 financing round Series A £12m with CIC + Merck Ventures + Pfizer Venture + Touchstone Innovations |
2016-06-28 |
| Storm Therapeutics–Touchstone Innovations: investment, 201606 financing round Series A totalling £12m incl investor Touchstone Innovations |
2016-06-28 |
| Itaconix–Revolymer: investment, 201606 acquisition $3m cash + $4m shares upfront plus $6m milestones in shares |
2016-06-20 |
| Vedanta Biosciences–BPCE: investment, 201606 financing round totalling $50m incl new investor Health for Life Capital (Seventure) |
2016-06-06 |
| Vedanta Biosciences–Invesco: investment, 201606 financing round totalling $50m incl new investor Invesco Asset Management |
2016-06-06 |
| Vedanta Biosciences–PureTech Health: investment, 201606 financing round totalling $50m incl investor PureTech Health plc |
2016-06-06 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201606 financing round totalling $50m incl new investor Rock Springs Capital |
2016-06-06 |
| Grünenthal–AstraZeneca: lesinurad, 201606– license excl for Europe + Latin America to Zurampic + fixed dose combi of lesinurad + allopurinol |
2016-06-02 |
| Vaccitech–Univ Oxford: investment, 201605 seed investment £10m from OSI at spin-out from Univ Oxford |
2016-05-12 |
| Evox Therapeutics–Univ Oxford: investment, 201605 Series A investment £10m from Oxford Sciences Innovation |
2016-05-11 |
| G1 Therapeutics–SEVERAL: investment, 201605 financing round Series C $47m led by new investor Cormorant Asset Management |
2016-05-11 |
| Blueberry Therapeutics–SEVERAL: investment, 201605 financing round £3m led by GM&C Life Sciences Fund managed by Catapult Ventures |
2016-05-05 |
| Foundry Innovation & Research 1–SEVERAL: investment, 201604 financing round Series B $7.5m incl existing investors Lightstone Ventures+NEA+Medtronic |
2016-04-12 |
| Agilent–Atturos: mass spectrometry, 201604– academic collaboration agreement |
2016-04-01 |
| Redx Pharma–SEVERAL: investment, 201603 placing £10m (net £9.37m) with 28.6m new ordinary shares at 35p/share |
2016-03-24 |
| Pila Pharma–Ario Pharma: TRPV1 antagonist, 201603 acquisition of XEN-D0501 assets by Pila Pharma |
2016-03-01 |
| Quethera–Wellcome Trust: grant, 201603 grant from Wellcome Trust Pathfinder Award Scheme |
2016-03-01 |
| Corvidia Therapeutics–AstraZeneca: investment, 201602 financing round Series A totalling $26m incl new + co- investor MedImmune |
2016-02-17 |
| Corvidia Therapeutics–AstraZeneca: ziltivekimab, 201602– license for COR-001 from AstraZeneca Emerging Innovations Unit |
2016-02-17 |
| Corvidia Therapeutics–SEVERAL: investment, 201602 financing round Series A $26m co-led by Sofinnova Partners + ATP |
2016-02-17 |
| Arcis:Altos–SEVERAL: investment, 201602 financing round £2.5m of Arcis Biotechnology |
2016-02-01 |
| Cell Medica–Baylor College: cancer immunotherapy, 2016– excl license + co-development agreement for cellular cancer immunotherapy |
2016-01-01 |
| Centauri Therapeutics–SEVERAL: investment, 201601 seed round 1st tranche £1.3m |
2016-01-01 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 ... 29 30 31 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
